Aurobindo Pharma reported INR39.08B in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
Cipla INR 29.71B 3.4B Jun/2026
Divis Laboratories Ltd INR 11.19B 1.2B Jun/2026
Dr.Reddys Laboratories INR 39.22B 1.52B Jun/2026
Hindustan Unilever INR 91.06B 6.27B Jun/2026
Sun Pharmaceuticals INR 37.02B 9.01B Jun/2026
UPL INR 51.47B 58.91B Jun/2026